$12 Million

OpGen

At-the-market Offering

OpGen is an commercial-stage molecular testing and bioinformatics company focused on developing and deploying precision medicine tools to combat infectious disease in global healthcare settings, helping to guide clinicians with more rapid information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen offers a full portfolio of in vitro diagnostic products and clinical laboratory services that employ state-of-the-art molecular diagnostics and bioinformatics/data analytics. Its QuickFISH products are a suite of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Clinical laboratory services utilize the Acuitas platform, including the MDRO Gene Test, the Resistome Test, microbial Whole Genome Sequence Analysis, and Acuitas Lighthouse MDRO Management System designed to detect, type, track, and trend antibiotic resistant organisms in real-time.